Navigation Links
Cardium Announces $4.0 Million Preferred Stock Financing And Reports On Exchange Listing Compliance
Date:4/5/2013

potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's newly-acquired To Go Brands® nutraceutical business. The Company's lead commercial product, Excellagen® topical gel for wound care management, has received FDA clearance for marketing and sale in the United States.  Cardium's lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. To Go Brands ® develops, markets and sells dietary supplements through established regional and national retailers.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements  

For example, there can be no assurance that the preferred stock offering can be completed as proposed or that the company will not be adversely affected by risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange; that certain elements of the financing will be approved by stockholders or that they will authorize a reverse stock split; that the company will satisfy the requirements of its compliance plan and will otherwise continue to satisfy the listing requirements of its exchange or that its shares can continue to be listed on a national exchange; that planned product development efforts and clinical studies can be performed in an efficient and effective manner; that regulatory approvals can be obtained in
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cardium Receives ISO Certification for Excellagen
2. Cardium Announces Presentaton at The 2013 Cell & Gene Therapy Forum
3. Cardium Presents Third Quarter 2012 Financial Results and Reports on Recent Developments
4. Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference
5. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
6. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation
7. Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences
8. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
9. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
10. MEI Pharma Announces $15.2 Million Registered Offering Of Common Stock
11. EntreMed Announces Changes to Board of Directors and CEO Appointment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 ... today announced that it has taken an exclusive worldwide ... FScan Ltd, a Durham University ... Pharma will pay an upfront fee, development and commercial ... Pharma has also taken an option for additional exclusive ...
(Date:7/28/2014)... Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH ), today announced ... June 30, 2014. Net loss for the ... to $8.3 million for the same period in 2013. The ... decrease in interest expense in the current period.  ... 2014 was $15.2 million, compared with net loss of $15.9 ...
(Date:7/28/2014)... YORK , July 28, 2014 Reportbuyer.com ... Global Bone Densitometers Market 2014-2018 ... A bone densitometry scan is a special type of ... a bone. It is used primarily to detect osteopenia ... low and the risk of fractures is high. The ...
Breaking Medicine Technology:Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 2Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 6Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 7Global Bone Densitometers Market 2014-2018 2Global Bone Densitometers Market 2014-2018 3Global Bone Densitometers Market 2014-2018 4Global Bone Densitometers Market 2014-2018 5
... MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm® ... Inc., a wholly-owned subsidiary of Reckitt Benckiser Group plc ... market adoption of Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual ... announcement of full-year 2010 financial results. ...
... Feb. 22, 2011 Prasco Laboratories ... supply agreement with Shire US Manufacturing, Inc. for ... Prasco, LLC is prepared to market the authorized ... Shire,s request, immediately upon any entrance into the ...
Cached Medicine Technology:MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010 2MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010 3
(Date:7/29/2014)... Some people can handle stressful situations better than ... Even identical twins show differences in how they ... pattern in the brains of genetically identical mice ... in stressful situations. , The findings, published ... eventually help researchers prevent potential consequences of chronic ...
(Date:7/29/2014)... 29, 2014 Healthcare staffing agency ... Nurses of Tomorrow Scholarship Competition winners:, ... NV ,     Racheal D., Freshman, Cerritos College ... Houston Community College in Houston, TX ... Medical Solutions hosts the Nurses of Tomorrow Scholarship ...
(Date:7/29/2014)... 29, 2014 Catalent Pharma Solutions, ... advanced delivery technologies for pharmaceutical, biologic, and consumer ... R&D Director and US Platform Leader of Pharmaceutical ... Drugs with Lipid-Based Formulations using Soft Capsule Delivery ... the Japan Society of Drug Delivery Systems (30-31 ...
(Date:7/29/2014)... The Affordable Care Act has created a ... Studies show that over 400 hospitals probably won’t survive ... tool that great hospitals use to survive the threat ... Their secret? Debriefing - the simple process of systematically ... an operational event. Debriefing is a standard procedure in ...
(Date:7/29/2014)... Dennis Thompson HealthDay Reporter ... live an average three years longer than people who don,t run, ... this study is that it appears that you can reap this ... every day, the 15-year study suggests. "People may not ... author Duck-chul Lee, an assistant professor of kinesiology at Iowa State ...
Breaking Medicine News(10 mins):Health News:A new brain-based marker of stress susceptibility 2Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2Health News:Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Running Could Add 3 Years to Your Lifespan 2Health News:Running Could Add 3 Years to Your Lifespan 3
... Dr. Neil Kurtz Resigns as President and Chief Executive Officer; ... Graham Appointed Acting Chief Executive Officer -, LA ... ) today announced that Neil Kurtz, M.D., is,resigning as President, ... of August 31, 2008. Dr. Kurtz is leaving TorreyPines,to assume ...
... genetic variation , , FRIDAY, Aug. 8 (HealthDay News) -- A ... salt intake and high blood pressure. , The study, which ... possible genetic factor that might make people more or less ... -- variants of a gene for angiotensinogen, a molecule that ...
... polar opposite diseases, but both depend upon dopamine in ... drug addicts get too much of it. Although the ... known, the way it works has been a mystery. ... Medicine has revealed that dopamine strengthens and weakens the ...
... release is available in French . , ... that patients who receive early treatment for Hepatitis C ... develop a rapid poly-functional immune response against HCV similar ... new study published in the Journal of Virology ...
... Delayed diagnosis, less successful surgery, pair of studies finds , , ... for prostate cancer may not be accurate for obese men, ... less likely to be effective for them, a new pair ... be diagnosed with an aggressive form of the disease," said ...
... in Senior Housing Growing; Adoption of Healthy Lifestyle ... ... the face of conventional,wisdom, which has long proven true, women live longer ... than ever are moving,into senior living residences nationwide. Historically female-dominated,senior living communities ...
Cached Medicine News:Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 2Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 3Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 4Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 5Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 6Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 7Health News:Too Much Salt Boosts Blood Pressure 2Health News:Why dopamine freezes parkinson patients and drives drug addicts 2Health News:Why dopamine freezes parkinson patients and drives drug addicts 3Health News:Early treatment is key to combating hepatitis C virus 2Health News:Obese Men Face Twin Threat From Prostate Cancer 2Health News:More Men Moving Into Senior Residences 2Health News:More Men Moving Into Senior Residences 3
Single step suture passage is made simple with Arthro-Pierce instruments. The low profile, highly sharpened tip allows easy passage through tissue in order to retrieve or apply suture....
12" suture passer...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Medicine Products: